Calidi Biotherapeutics (CLDI) Cash & Equivalents (2022 - 2025)

Calidi Biotherapeutics has reported Cash & Equivalents for 4 years, with the latest figure at $219000.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 97.72% year-over-year to $219000.0; the trailing twelve-month figure through Dec 2025 stood at $219000.0 (down 97.72% YoY), and the FY2025 full-year result was $219000.0, down 97.72% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $219000.0, down from $10.4 million in the prior quarter.
• The five-year high for Cash & Equivalents was $10.6 million in Q1 2025, with the low at $218000.0 in Q4 2022.
• Average Cash & Equivalents over 4 years is $3.7 million, with a median of $1.1 million recorded in 2024.
• Year-over-year, Cash & Equivalents surged 2040.85% in 2024 and tumbled 97.72% in 2025.
• Tracing CLDI's Cash & Equivalents over 4 years: stood at $218000.0 in 2022, then jumped by 105.5% to $448000.0 in 2023, then surged by 2040.85% to $9.6 million in 2024, then plunged by 97.72% to $219000.0 in 2025.
• The last three Cash & Equivalents figures came in at $219000.0 (Q4 2025), $10.4 million (Q3 2025), and $5.3 million (Q2 2025), per Business Quant data.

Peer Comparison